120484-50-6

Basic information

• Product Name: 2'-FLUORO-6'-METHOXYACETOPHENONE
• Synonyms: 2'-FLUORO-6'-METHOXYACETOPHENONE;2-FLUORO-6-METHOXYACETOPHENONE;1-(2-FLUORO-6-METHOXYPHENYL)ETHANONE
• CAS NO: 120484-50-6
• Molecular Formula: C₉H₉FO₂
• Molecular Weight: 168.16
• Product Categories: Aromatic Acetophenones & Derivatives (substituted)
• Mol File: 120484-50-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 217℃
• Flash Point: 83℃
• Appearance: /
• Density: 1.127
• Refractive Index: 1.508
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2'-FLUORO-6'-METHOXYACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-FLUORO-6'-METHOXYACETOPHENONE(120484-50-6)
• EPA Substance Registry System: 2'-FLUORO-6'-METHOXYACETOPHENONE(120484-50-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 120484-50-6(Hazardous Substances Data)

Usage

Uses

1-(2-Fluoro-6-methoxyphenyl)ethanone is a useful synthetic intermediate. It is used to prepare spiro[2H-1-benzopyran-2,4''-piperidine] derivatives as glycine transport inhibitors.

Upstream product

• 456-49-5 1-fluoro-3-methoxybenzene 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 120484-49-3 1-(2-fluoro-6-methoxyphenyl)ethan-1-ol 
• 146137-74-8 2-fluoro-6-methoxybenzaldehyde 
• 75-16-1 methylmagnesium bromide 
• 94088-46-7 2-fluoro-6-methoxybenzonitrile 

Downstream Products

• 1187732-44-0 1-[2-(benzylsulfanyl)-6-methoxyphenyl]ethanone 
• 1354928-62-3 C₁₇H₁₁FO₄ 
• 1408085-07-3 2-((4-Amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(3-fluorophenyl)-5-methoxy-4H-chromen-4-one 
• 1408085-09-5 2-((4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1408085-12-0 2-((4-amino-3-(3-fluoro-5-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1408085-13-1 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1408085-14-2 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1408085-20-0 2-(1-(4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1408085-85-7 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 4-methylbenzenesulfonate 
• 1408086-28-1 2-(1-(4-amino-3-(3-hydroxyprop-1-ynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1408087-20-6 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-5-morpholino-4H-chromen-4-one 
• 1408087-54-6 2-acetyl-3-fluorophenyl acetate 
• 1408087-59-1 3-(3-fluorophenyl)-5-methoxy-2-methyl-4H-chromen-4-one 
• 1408087-61-5 2-(bromomethyl)-3-(3-fluorophenyl)-5-methoxy-4H-chromen-4-one 

Relevant articles and documents

Intramolecular C-H and C-F Bond Oxygenation Mediated by a Putative Terminal Oxo Species in Tetranuclear Iron Complexes

Herein we report the intramolecular arene C-H and C-F bond oxygenation by tetranuclear iron complexes. Treatment of [LFe3(PhPz)3OFe][OTf]2 (1) or its fluorinated analog [LFe3(F2ArPz)3OFe][OTf]2 (5) with iodosobenzene results in the regioselective hydroxylation of a bridging pyrazolate ligand, converting a C-H or C-F bond into a C-O bond. The observed reactivity suggests the formation of terminal and reactive Fe-oxo intermediates. With the possibility of intramolecular electron transfer within clusters in 1 and 5, different reaction pathways (FeIV-oxo vs FeIII-oxo) might be responsible for the observed arene hydroxylation.

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Hydroxylated nebivolol metabolites

Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.